Related Experiment Video
Updated: Dec 9, 2025
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
502
Proteomic characterization of obesity-related nephropathy
Ralph Wendt1, Tianlin He2, Agnieszka Latosinska2
1Department of Nephrology and Kuratorium for Dialysis and Transplantation Renal Unit, Hospital St Georg, Leipzig, Germany.
Clinical Kidney Journal
|September 9, 2020
Summary
Obesity-related kidney disease lacks understanding. Urinary peptides, particularly collagen fragments, are linked to body mass index (BMI) and kidney function, suggesting fibrosis as a cause.
Area of Science:
- Nephrology
- Proteomics
- Metabolomics
Background:
- Obesity-related nephropathy lacks clear pathophysiological understanding.
- Definitive diagnostic biomarkers for obesity-related kidney disease are currently unavailable.
Purpose of the Study:
- Investigate the association between urinary peptides and body mass index (BMI).
- Explore the relationship between urinary peptides and renal function.
- Identify potential biomarkers for obesity-related nephropathy.
Main Methods:
- Analyzed proteome data from 4015 individuals.
- Examined associations between urinary peptides, BMI, and estimated glomerular filtration rate (eGFR).
- Developed and validated a peptide-based classifier in an independent cohort.
Main Results:
- Identified 365 urinary peptides significantly associated with BMI, predominantly collagen fragments.
- Most identified peptides showed concordant association with eGFR.
- A 150-peptide classifier distinguished obese from non-obese individuals with preserved kidney function (AUC=0.93).
Conclusions:
- Urinary peptides, especially collagen fragments, suggest a molecular link between obesity and kidney fibrosis.
- Fibrosis may be a key mechanism in obesity-related nephropathy.
- Urinary peptides hold potential as biomarkers for obesity-related kidney disease.
More Related Videos
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
96
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
96
01:24Nephrotic Syndrome I : Introduction
337
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
337
01:26Nephrotic Syndrome II : Assessment and Medical Management
114
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
114
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
138
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
138
01:33Proteomics
9.0K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
9.0K
01:24Obesity
1.0K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.0K